Stock KNSA KINIKSA PHARMACEUTICALS, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Kiniksa Pharmaceuticals, Ltd.

Equities

KNSA

BMG5269C1010

Real-time Estimate Cboe BZX
Other stock markets
 09:24:43 03/05/2024 pm IST 		5-day change 1st Jan Change
19.74 USD +1.83% Intraday chart for Kiniksa Pharmaceuticals, Ltd. +10.51% +12.66%
23/04 Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises MT
23/04 Transcript : Kiniksa Pharmaceuticals, Ltd., Q1 2024 Earnings Call, Apr 23, 2024

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Wedbush Adjusts Kiniksa Pharmaceuticals' PT to $30 From $28, Maintains Outperform Rating
MT
Wedbush Lifts Kiniksa Pharmaceuticals' PT to $25 From $23 Ahead of Planned Q1 Reporting of Initial Data on KPL-404; Maintains Outperform Rating
MT
Wedbush Adjusts Kiniksa Pharmaceuticals Price Target to $23 From $21, Maintains Outperform Rating
MT
Wedbush Raises Kiniksa Pharmaceuticals Price Target to $21 From $20, Maintains Outperform Rating
MT
JPMorgan Adjusts Kiniksa Pharmaceuticals' Price Target to $20 From $19, Keeps Overweight Rating
MT
Wedbush Lowers Kiniksa Pharmaceuticals' Price Target to $20 From $26, Adjusts Commercial Ramp Assumptions for Arcalyst; Keeps Outperform Rating
MT
Wedbush Lifts Price Target on Kiniksa Pharmaceuticals to $26 From $25, Keeps Outperform Rating
MT
Wedbush Lifts Price Target for Kiniksa Pharmaceuticals to $25 From $24, Maintains Outperform Rating
MT
Wedbush Lowers Price Target for Kiniksa Pharmaceuticals to $24 From $28, Maintains Outperform Rating
MT
Wedbush Lifts Price Target on Kiniksa Pharmaceuticals to $28 From $25.91; Outperform Rating Kept
MT
BofA Securities Adjusts Kiniksa Pharmaceuticals' Price Target to $34 From $37, Reiterates Buy Rating
MT
JPMorgan Adjusts Price Target on Kiniksa Pharmaceuticals to $27 From $30, Reiterates Overweight Rating
MT
Wedbush Lifts Kiniksa Pharmaceuticals' Price Target to $26 From $24; Outperform Rating Kept
MT
KINIKSA PHARMACEUTICALS : Wedbush Cuts Price Target on Kiniksa Pharmaceuticals to $24 From $32, Citing Vixarelimab Launch Timeline; Outperform Rating Kept
MT
KINIKSA PHARMACEUTICALS : Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $32 From $35 on Estimated Mavrilimumab Launch Date; Outperform Rating Kept
MT
KINIKSA PHARMACEUTICALS : Evercore ISI Starts Kiniksa Pharmaceuticals at Outperform with $25 Price Target
MT
KINIKSA PHARMACEUTICALS : Wedbush Adjusts Price Target on Kiniksa Pharmaceuticals to $35 From $38, Keeps Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KNSA Stock
  4. News Kiniksa Pharmaceuticals, Ltd.
  5. Analyst Reco.